Nanosonics share price slides lower on business update

Nanosonics shares are falling on Wednesday. Here's why…

| More on:
young female doctor with digital tablet looking confused.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Nanosonics share price is in the red on Wednesday
  • This follows the release of a business update
  • Nanosonics revealed that its direct sales model transition in North America is going well

The Nanosonics Ltd (ASX: NAN) share price is dropping on Wednesday.

In morning trade, the infection prevention company's shares are down 1.5% to $3.74.

Why is the Nanosonics share price falling?

The weakness in the Nanosonics share price on Wednesday has been driven by the release of a business update.

This update was in relation to the company's direct sales model transition in North America which was announced in February.

According to the release, the direct sales model transition is progressing well with the transfer of GE customers currently in progress and a significant number of accounts already set up by Nanosonics.

The release notes that GE has been supporting Nanosonics with the transition by communicating with all of their trophon customers about the new arrangements being implemented for the ongoing provision of trophon products.

Furthermore, the relevant GE customer data has been supplied to Nanosonics and the company has communicated with all these customers to set up direct trading accounts. A significant number of these accounts are now in place. Management expects that the transition will be completed for the majority of customers by 30 June 2022.

Also supporting the transition will be a number of former GE High Level Disinfection team members that have joined Nanosonics. These include the previous Head of the GE High Level Disinfection team, a GE operations lead who was responsible for the supply and logistics of trophon products to all GE customers, and a number of sales managers.

Trading update

During the third quarter, Nanosonics' global installed base grew to 28,900. This is up a modest 2.6% from 28,160 units at the end of December. It could be this subdued growth that is weighing on the Nanosonics share price today.

Nevertheless, management revealed that it expects its full-year revenue to be in line with current market consensus estimates.

Furthermore, Nanosonics' Chief Executive Officer and President, Michael Kavanagh, believes the transition will benefit the company. He commented:

The continued transition to a more direct sales channel model in North America brings many benefits to Nanosonics and its customers. Our North American team can now manage the overall growth strategy associated with new installed base, upgrade adoption and consumables usage. This deeper relationship with our North American customers together with our corresponding infrastructure expansion also supports planned product expansion beyond trophon.

We are very pleased with the ongoing progress being made with the transition to the updated sales model. Our North American team and the GE healthcare ultrasound team continue to collaborate well ensuring the current and future infection prevention needs of all customers and their patients are fully met.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics Limited. The Motley Fool Australia has positions in and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »